CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 13:41:17 2024-05-31 EDT | ||
| 6.86 EUR | +17.47% |
|
| Current month | +259.16% | ||
| 1 month | +259.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 6.86 | +17.47% |
| 24-05-30 | 5.84 | -5.04% |
| 24-05-29 | 6.15 | -5.82% |
| 24-05-28 | 6.53 | -16.17% |
| 24-05-27 | 7.79 | +4.99% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:41 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM656V |
| ISIN | DE000VM656V5 |
| Date issued | 2023-12-15 |
| Strike | 378.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.79 € |
|---|---|
| Lowest since issue | 0.83 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
